Form 4: Xilio Director Buys 5,000 Shares Post Split

Director James S. Shannon reported buying 5,000 Xilio shares at a weighted average $8.79, lifting his direct stake to 10,000 shares after a 1-for-14 reverse split.

Summary

• On 2026-03-26, Director James S. Shannon acquired 5,000 shares of Xilio Therapeutics (XLO) common stock at a weighted average price of $8.79; individual trades ranged from $8.6758 to $9.2499.
• Following the transaction, Shannon directly beneficially owns 10,000 shares.
• Share counts reflect a 1-for-14 reverse stock split effective 2026-03-13.
• The filing was executed by Kevin Brennan, Attorney-in-Fact, on 2026-03-30.
• Relationship to issuer: Director (not a 10% owner or officer, per the designation).
• Note: A footnote states the securities were “sold” in multiple transactions, which appears inconsistent with Transaction Code P (purchase) and the “A” (acquired) designation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral-to-modestly positive: an insider buy is encouraging, but the small size and a footnote inconsistency limit the strength of the signal.

Positives

• Insider acquisition by a director: 5,000 shares purchased at a weighted average price of $8.79.
• Post-transaction direct beneficial ownership stands at 10,000 shares, indicating an increased personal stake.

Negatives

• Footnote language states the securities were “sold,” conflicting with purchase code and ‘acquired’ status, creating ambiguity.
• The transaction size (5,000 shares; roughly $44,000 notional) is modest, which can limit signaling value.

Future Outlook

No forward-looking statements or guidance provided.

Industry Context

StockSavvy.ai notes insider open-market purchases in small-cap biotech are often viewed as a mild confidence signal, though their impact depends on size and context; the 1-for-14 reverse split aligns with common micro-cap practices to consolidate shares and elevate per-share price.

Comparison to Industry Standards

• Relative transaction size: At roughly $44,000 notional, this buy is below the typical $100,000–$500,000 insider purchases that tend to draw stronger investor attention in small-cap biotech.
• Reverse split magnitude: A 1-for-14 consolidation is within the common 1-for-10 to 1-for-20 range seen among micro-cap biotechs seeking higher per-share trading prices.
• Signal strength vs peers: Insider purchases can be a positive indicator, but modest size and absence of concurrent company updates (e.g., clinical catalysts or financing announcements) generally temper the signaling effect compared to higher-profile insider buys sometimes seen at peer biotechs.

Stakeholder Impact

• Shareholders: A director’s open-market purchase may be interpreted as a modest vote of confidence.
• Market dynamics: The 1-for-14 reverse split changes share count and per-share price mechanics, which can affect trading dynamics and liquidity.
• Governance/oversight: Increased director ownership can better align incentives with shareholders.

Key Dates

Keywords

Xilio Therapeutics, XLO, insider purchase, Form 4, reverse stock split, James S. Shannon, beneficial ownership, biotech, common stock